Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IPH 6401

Next Previous
Drug Profile

IPH 6401

Alternative Names: IPH-64; IPH-6401; SAR-445514; SAR’514

Latest Information Update: 26 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innate Pharma
  • Developer Innate Pharma; Sanofi
  • Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Amyloid light-chain amyloidosis; Multiple myeloma
  • No development reported Cancer

Most Recent Events

  • 09 Jun 2025 Sanofi terminates phase I/II clinical trials in Amyloid light-chain amyloidosis and multiple myeloma (Monotherapy, Second-line therapy or greater) in United Kingdom, Spain, Italy, Hungary, Czech Republic, Belgium (SC) based on sponsor decision not driven by any safety concerns (NCT05839626)
  • 28 Jan 2025 No recent reports of development identified for preclinical development in Cancer in France (Parenteral)
  • 15 May 2023 Phase-I/II clinical trials in Amyloid light-chain amyloidosis (Monotherapy, Second-line therapy or greater) in United Kingdom, Spain, Italy, Hungary, Czech Republic, Belgium (SC) (NCT05839626)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top